Drugs / ROMYELOCEL-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02282215 | Dec 2014 → Sep 2017 | acute myeloid leukemia, infectious disease, neutropenia | Cellerant Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROMYELOCEL-L | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137339 ↗ |
| Known as | CLT-008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02282215 ↗ |
| Modality | Cell therapy | “a human allogeneic myeloid progenitor cell product” NCT02282215 ↗ |
| Route | Intravenous | “Single intravenous infusion” NCT02282215 ↗ |